Detailed examinations of various tumors indicate positive outcomes, with the combination therapy demonstrating promising results in targeted mesothelin-positive solid tumors, GD-2 expressing neuroblastoma, CD-19-positive tumors, CD-22-positive tumors, CD-30-directed therapy, and CD133-directed CAR-T cell-based combination therapy. This evidence concerns the gene CD22 and neuroblastoma.